Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): Extended follow-up of a phase 3, randomised, open-label study

Grant A. McArthur*, Paul B. Chapman, Caroline Robert, James Larkin, John B. Haanen, Reinhard Dummer, Antoni Ribas, David Hogg, Omid Hamid, Paolo A. Ascierto, Claus Garbe, Alessandro Testori, Michele Maio, Paul Lorigan, Celeste Lebbé, Thomas Jouary, Dirk Schadendorf, Stephen J. O'Day, John M. Kirkwood, Alexander M. EggermontBrigitte Dréno, Jeffrey A. Sosman, Keith T. Flaherty, Ming Yin, Ivor Caro, Suzanne Cheng, Kerstin Trunzer, Axel Hauschild

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

717 Scopus citations

Fingerprint

Dive into the research topics of 'Safety and efficacy of vemurafenib in BRAF<sup>V600E</sup> and BRAF<sup>V600K</sup> mutation-positive melanoma (BRIM-3): Extended follow-up of a phase 3, randomised, open-label study'. Together they form a unique fingerprint.

Medicine & Life Sciences